MYBPC3 gene variations in hypertrophic cardiomyopathy patients in India

Reena R Tanjore1, Advithi Rangaraju, P G Kerkar

  • 1Department of Genetics, Osmania University, Jamai Osmania PO, Hyderabad, Andhra Pradesh, India.

Insights

This study identified a novel frameshift mutation in the MYBPC3 gene in Indian patients with hypertrophic cardiomyopathy (HCM). This mutation leads to a truncated protein, offering new insights into HCM pathogenesis and genetic screening relevance in India.

Area of Science:

  • Genetics
  • Cardiology
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is an inherited autosomal dominant disorder affecting cardiac muscle.
  • Mutations in the MYBPC3 gene are a significant cause of HCM, accounting for 15% of cases.
  • Cardiac myosin-binding protein C (MyBPC) is crucial in heart muscle function.

Purpose of the Study:

  • To screen specific exons (16, 18, 19, 22, 24, 28, 30, 31, 34) of the MYBPC3 gene in Indian patients diagnosed with HCM.
  • To identify novel mutations and genetic variations within the MYBPC3 gene associated with HCM in the Indian population.

Main Methods:

  • Genomic DNA was isolated from 95 HCM patients and 60 controls from CARE Hospital, India.
  • Polymerase chain reaction (PCR) and single-stranded conformational polymorphism (SSCP) analysis were employed to screen targeted MYBPC3 gene exons.

Main Results:

  • A novel frameshift mutation (D570fs) was discovered in exon 19 of the MYBPC3 gene.
  • A novel single nucleotide polymorphism (SNP) was identified in codon 1093 of exon 31 (GGC/GGT).
  • Seven known intronic SNPs and one known missense mutation (D770N) were also observed in the study population.

Conclusions:

  • The novel D570fs mutation likely results in a truncated MyBPC protein, potentially via nonsense-mediated decay, impacting myosin and titin binding.
  • The novel synonymous SNP in exon 31 may influence translation efficiency through altered codon-anticodon interactions.
  • MYBPC3 gene screening is clinically relevant for diagnosing and understanding HCM in the Indian population.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...